Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic G. Miranda-Zazueta; J.A. González-Regueiro; I. García-Juárez; C. Moctezuma-Velázquez; F.J. López-Díaz; B. Pérez-González; L.F. Uscanga-Domínguez; M. Peláez-Luna;

Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases R. Tapia-Sosa; F. Hernández-Cabral; A. Gabutti; V.M. Páez-Zayas; I. García-Juárez;

Should mycophenolate mofetil be first-line treatment in autoimmune hepatitis? J.A. Torres-Díaz; I. García-Juárez;